Isosorbide Mononitrate Tablet Global Market Report 2025

The isosorbide mononitrate tablet market size has grown strongly in recent years. It will grow from$1.14 billion in 2024 to $1.21 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth during the historic period can be attributed to the growing elderly population, the increasing incidence of heart-related conditions, greater awareness of heart health, the availability of generic drugs, and public health campaigns.

The isosorbide mononitrate tablet market size is expected to see strong growth in the next few years. It will grow to$1.51 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to regulatory approvals and patent expirations, the increasing adoption of generic drugs, growth in lifestyle-related risk factors, government initiatives for cardiovascular disease management, improvements in diagnostic infrastructure, and awareness campaigns. Key trends during this period include advancements in extended-release formulations, technological innovations, the rise of digital health platforms and e-commerce, integration of digital health technologies, and the combination of isosorbide mononitrate with other cardiovascular drugs.

The increasing prevalence of cardiovascular diseases (CVDs) is driving the growth of the isosorbide mononitrate tablet market. CVDs, including coronary artery disease, heart failure, and hypertension, are becoming more widespread due to factors such as unhealthy diets high in saturated fats, trans fats, sodium, and added sugars, which contribute to conditions such as obesity, hypertension, and high cholesterol. Isosorbide mononitrate tablets are commonly used to manage these diseases by relaxing and widening blood vessels, which improves blood flow, reduces the heart's workload, and alleviates chest pain (angina). According to a report from the Australian Institute of Health and Welfare in December 2023, coronary heart disease (CHD) deaths in Australia have been increasing, with 14,100 deaths in 2021 rising to 14,900 in 2022. This growing prevalence of cardiovascular diseases is significantly contributing to the demand for effective treatments, such as isosorbide mononitrate tablets.

The increasing adoption of online pharmacies is further propelling the growth of the isosorbide mononitrate tablet market. Consumers are seeking greater convenience, affordability, and accessibility to medications without the need to visit physical pharmacies. Online pharmacies offer home delivery, competitive pricing, and improved availability, particularly for patients managing chronic conditions such as cardiovascular diseases. A survey conducted by the Alliance for Safe Online Pharmacies (ASOP) in September 2023 revealed that 52% of Americans aged 18 and older had used an online pharmacy, showing a notable increase from previous years. This surge in online pharmacy usage is making it easier for patients to access essential medications, including isosorbide mononitrate tablets, fueling market growth.

Pharmaceutical companies are focusing on the development of extended-release (ER) formulations of isosorbide mononitrate to improve patient compliance and enhance treatment outcomes. ER tablets provide sustained therapeutic effects by gradually releasing the medication over an extended period, reducing the need for frequent dosing and ensuring consistent blood levels of the drug. In February 2024, Zydus Lifesciences Limited received approval from the U.S. Food and Drug Administration (FDA) to market isosorbide mononitrate extended-release tablets in strengths of 30 mg, 60 mg, and 120 mg. These tablets help prevent chest pain (angina) in patients with coronary artery disease and offer a more convenient treatment option for those requiring long-term management, further contributing to the growth of the isosorbide mononitrate tablet market.

Major players in the isosorbide mononitrate tablet market are Pfizer Inc., Merck & Co. Inc., AstraZeneca PLC, Abbott Laboratories Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Zydus Lifesciences Limited, Recipeharm, Torrent Pharmaceuticals Ltd., Micro Labs Ltd., Lotus Pharmaceuticals, Healthy Inc., Qilu Pharmaceutical Co. Ltd, Lunan Pharmaceutical Group, Johnlee Pharmaceuticals Pvt. Ltd., Niksan Pharmaceutical, Shandong Keyuan Pharmaceutical, and Prevego Healthcare & Research Private Limited.

North America was the largest region in the isosorbide mononitrate tablet market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in isosorbide mononitrate tablet report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the isosorbide mononitrate tablet market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Isosorbide mononitrate tablets are long-acting nitrate medications primarily used to prevent and control chest pain (angina) associated with coronary artery disease. The medication works by relaxing and dilating blood vessels, particularly in the heart, which allows for increased blood and oxygen flow while reducing the heart's workload. Unlike fast-acting nitrates used for immediate relief, isosorbide mononitrate is taken regularly as a maintenance therapy to reduce the frequency and severity of angina attacks and improve overall cardiovascular function.

The main dosage forms of isosorbide mononitrate tablets are immediate-release tablets and extended-release tablets. Immediate-release tablets are designed to dissolve quickly, allowing for rapid absorption and fast relief, especially for conditions such as angina. These tablets are used for various indications, including angina pectoris, heart failure, and hypertension, and are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The isosorbide mononitrate tablet market research report is one of a series of new reports that provides isosorbide mononitrate tablet market statistics, including the isosorbide mononitrate tablet industry global market size, regional shares, competitors with the isosorbide mononitrate tablet market share, detailed isosorbide mononitrate tablet market segments, market trends, and opportunities, and any further data you may need to thrive in the isosorbide mononitrate tablet industry. This isosorbide mononitrate tablet market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The isosorbide mononitrate tablet market consists of sales of dilatrate-SR, isochron, monoket, and imdur, pediatric and geriatric-adjusted tablets, and combination products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.